| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8722757 | HPB | 2018 | 8 Pages |
Abstract
Although testing of serum CA 19-9 has considerable limitations, CA 19-9 remains the most used serum tumor marker for surveillance after surgical resection of pancreatic cancer. Further studies are needed to assess the role of serum tumor marker testing in the detection of recurrent pancreatic cancer and to optimize surveillance strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Lois A. Daamen, Vincent P. Groot, Hanne D. Heerkens, Martijn P.W. Intven, Hjalmar C. van Santvoort, I. Quintus Molenaar,